Treatment and delay of outset of Parkinson's disease

Details Treatment and delay of outset of Parkinson's disease Treatment and delay of outset of Parkinson's disease

2003-10-31

2010-06-01

Kolker, Daniel E. (Department: 1649)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C424S130100, C424S185100, C424S193100, C424S278100

Reexamination Certificate

active

07727957

ABSTRACT:
The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.

REFERENCES:
patent: 4883666 (1989-11-01), Sabel et al.
patent: 5576184 (1996-11-01), Better et al.
patent: 5589154 (1996-12-01), Anderson
patent: 5753624 (1998-05-01), McMichael
patent: 5780587 (1998-07-01), Potter
patent: 5807741 (1998-09-01), Brown et al.
patent: 5851996 (1998-12-01), Kline
patent: 5958883 (1999-09-01), Snow
patent: 6504080 (2003-01-01), Van Der Putten
patent: 6710226 (2004-03-01), Schenk
patent: 6743427 (2004-06-01), Schenk
patent: 6761888 (2004-07-01), Schenk
patent: 6780971 (2004-08-01), Wolozin et al.
patent: 6787138 (2004-09-01), Schenk
patent: 6787139 (2004-09-01), Schenk
patent: 6787140 (2004-09-01), Schenk
patent: 6787143 (2004-09-01), Schenk
patent: 6787144 (2004-09-01), Schenk
patent: 6787523 (2004-09-01), Schenk
patent: 6858704 (2005-02-01), Kim
patent: 6866849 (2005-03-01), Schenk
patent: 6866850 (2005-03-01), Schenk
patent: 6890535 (2005-05-01), Schenk
patent: 6923964 (2005-08-01), Schenk
patent: 6946135 (2005-09-01), Schenk
patent: 6972127 (2005-12-01), Schenk
patent: 7014855 (2006-03-01), Schenk
patent: 7060464 (2006-06-01), Kim
patent: 7138255 (2006-11-01), Vodyanoy et al.
patent: 7479482 (2009-01-01), Frangione et al.
patent: 2002/0094335 (2002-07-01), Chalifour et al.
patent: 2002/0151464 (2002-10-01), Wolozin et al.
patent: 2002/0160394 (2002-10-01), Wu
patent: 2002/0187157 (2002-12-01), Jensen et al.
patent: 2002/0197258 (2002-12-01), Ghanbari et al.
patent: 2003/0086938 (2003-05-01), Jensen et al.
patent: 2003/0165496 (2003-09-01), Basi et al.
patent: 2003/0166558 (2003-09-01), Frangione et al.
patent: 2004/0136993 (2004-07-01), Schenk et al.
patent: 2004/0137523 (2004-07-01), Vodyanoy et al.
patent: 2004/0146521 (2004-07-01), Schenk et al.
patent: 2004/0197831 (2004-10-01), Weksler et al.
patent: 2005/0037013 (2005-02-01), Schenk et al.
patent: 2005/0123544 (2005-06-01), Schenk et al.
patent: 2005/0176078 (2005-08-01), Allsop et al.
patent: 2005/0196818 (2005-09-01), Chilcote et al.
patent: 2005/0198694 (2005-09-01), Chilcote et al.
patent: 2005/0203010 (2005-09-01), Kim
patent: 2005/0255113 (2005-11-01), Huston et al.
patent: 2006/0058233 (2006-03-01), Schenk et al.
patent: 2006/0259986 (2006-11-01), Chilcote et al.
patent: 0 613 007 (1994-08-01), None
patent: WO 91/16819 (1991-11-01), None
patent: WO 95/06407 (1995-03-01), None
patent: WO 99/06545 (1999-02-01), None
patent: WO 99/06545 (1999-02-01), None
patent: WO 99/27944 (1999-06-01), None
patent: WO 99/40191 (1999-08-01), None
patent: WO 99/50300 (1999-10-01), None
patent: WO 99/60024 (1999-11-01), None
patent: WO 00/18917 (2000-04-01), None
patent: WO 00/18917 (2000-04-01), None
patent: WO 00/72876 (2000-12-01), None
patent: WO 00/72876 (2000-12-01), None
patent: WO 00/72880 (2000-12-01), None
patent: WO 00/72880 (2000-12-01), None
patent: WO 01/06989 (2001-02-01), None
patent: WO 01/06989 (2001-02-01), None
patent: WO 01/53457 (2001-07-01), None
patent: WO 01/53457 (2001-07-01), None
patent: WO 01/60794 (2001-08-01), None
patent: WO 01/60794 (2001-08-01), None
patent: WO 03/000714 (2003-01-01), None
patent: WO 03/000714 (2003-01-01), None
patent: WO 03/045128 (2003-06-01), None
patent: WO 03/045128 (2003-06-01), None
patent: WO 2004/009625 (2004-01-01), None
patent: WO 2004/009625 (2004-01-01), None
patent: WO 2004/041067 (2004-05-01), None
patent: WO 2004/041067 (2004-05-01), None
patent: WO 2005/013889 (2005-02-01), None
patent: WO 2005/047860 (2005-05-01), None
patent: WO 2005/047860 (2005-05-01), None
patent: WO 2006/020581 (2006-02-01), None
patent: WO 2006/020581 (2006-02-01), None
patent: WO 2006/045037 (2006-04-01), None
patent: WO 2006/045037 (2006-04-01), None
patent: WO 2007/012061 (2007-01-01), None
patent: WO 2007/021255 (2007-02-01), None
patent: WO 2008/103472 (2008-08-01), None
Kotzbauer et al. (Oct. 2001) “Lewy Body Pathology in Alzheimer's Disease.” Journal of Molecular Neuroscience 17(2): 225-232.
Wakabayashi et al. (Oct. 1999) “Widespread occurrence of a-synuclein/NCAP-immunoreactive neuronal inclusions in juveline and adult-onset Hallervorden-Spatz disease with Lewy bodies.” Neuropathology and Applied Neurobiology 25(5): 363-368.
Ma et al. (Apr. 2003) “a-synuclein aggregation and neurodegenerative diseases.” Journal of Alzheimer's Disease 5(2): 139-148.
Wakabayashi et al. (Nov. 1998) “Accumulation of a-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy.” Acta Neuropathol 96(5): 445-452.
Goldsby et al. (2002) Kuby Immunology 4th Ed. Chapter 18 “Vaccines” (pp. 449-465).
Hansen et al, “neurobiology of disorders with lewy bodies,” Functional Neurobiology of Aging. Hof and Mobbs, Eds. (2001).
Masliah et al. (2005). Neuron. 46, 857-868.
Vickers, J. Drugs Aging 2002 (vol. 19, No. 7), 487-494.
Primavera et al (1999). Journal of Alzheimer's disease. 1, 183-193.
Skipper et al.(2002). NeruoToxicology. 23, 530-514.
Di Monte et al. (2002). NeuroToxicology. 23, 487-502.
Hooper et al (2000). Cellular Peptidases in Immune Functions and Diseases 2 (Langer and Ansorge, Eds). Plenum Publishers.
Schenk (2002). Nature Reviews. 3, 824-828.
Su e al (1999). Brain Research. 818, 105-117.
Lee et al (2002). PNAS. 99, 8968-8973.
Alves da Costa (2003. Current Molecular Medicine 3:17-24).
Sidhu (2004. FASEB J. 18:637-647).
Jendroska 1996 (Movement Disorders 11(6):647-653).
Chapman, P.F., “Model behaviour,”Nature,408:915-916 (2000).
Conway et al., “Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy,”PNAS,97(2):571-676 (2000).
Demattos et al., “Peripheral anti A β antibody alters CNS and plasma A β clearance and decreases brain A β burden in a mouse model of Alzheimer's disease,”PNAS,10:1-6 (2001).
Elan, “Elan and AHP provide an update on the phase 2A Clinical Trial of AN-1782,” Press Release of Jan. 28, 2002.
Elan, “Elan and Wyeth provide update on status of Alzheimer's collaboration,” Press Release of Mar. 1, 2002.
Esiri, M.M., “Is an effective immune intervention for Alzheimer's disease in prospect?,”Trends in Pharmacological Sciences,22(1):2-3, (Jan. 2001).
Frenkel et al., “N-terminal EFRH sequence of Alzheimer's β-amyloid peptide represents the epitope of its anti-aggregating antibodies,”Journal of Neuroimmunology,88:85-90 (1998).
Frenkel et al., “Immunization against Alzheimer's β-amyloid plaques via EFRH phage administration,”PNAS,97(21):11455-11459 (2000).
Frenkel et al., “High affinity binding of monoclonal antibodies to the sequential epitope EFRH of β-amyloid peptide is essential for modulation of fibrillar aggregation,”Journal of Neuroimmunology,95:136-142 (1999).
Friedland et al., “Neuroimaging of Vessel Amyloid in Alzheimer's Disease a,b,” fromCerebrovascular Pathology in Alzheimer's Disease,eds. de la Torre and Hachinski, New York Academy of Science, NY, NY, pp. 242-247 (1997).
Games et al., “Alzheimer-type neuropathology in transgeneic mice overexpressing V717F β-amyloid precursor protein,”Nature,373(6514):523-527 (1995).
Grubeck-Loebenstein et al., “Immunization with β-amyloid: could T-cell activation have a harmful effect?,”TINS,23(3):114 (2000).
Jen et al., “Preparation and purification of antisera against different regions or isoforms of β-amyloid precursor protein,”Brain Research Protocols,2:23-30 (1997).
Jobling et al., “Analysis of structure and function of the

Affiliated with

Also associated with

Rating

Treatment and delay of outset of Parkinson's disease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment and delay of outset of Parkinson's disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment and delay of outset of Parkinson's disease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4245062